Rabies Treatment & Management
- Author: Sandra G Gompf, MD, FACP, FIDSA; Chief Editor: Burke A Cunha, MD more...
Approach Considerations
When the patient presents with a bite, wound cleansing, debridement, and careful exploration for foreign body (eg, broken tooth) are essential; this should take at least 10 minutes. Generally, leave wounds to heal by secondary intention to permit drainage of wound fluids and prevent infection.[14, 18]
Inpatient care
Inpatient care of patients with rabies may be needed if wounds are extensive or are on the face and hands, if surgical repair or replacement of blood loss is required, or if infection occurs.
Transfer
For a patient with an illness consistent with rabies, transfer to a tertiary care center with intensive care support and capability of providing timely diagnostic workup is essential.
Follow-up
Coordinate follow-up evaluations of patients with the primary caregiver, the local health department, and, if applicable, the veterinarian who quarantined the animal.
Preexposure Prophylaxis or Immunization
Preexposure, active prophylaxis or immunization is recommended for veterinarians, veterinary students, persons who regularly explore or hike in caves, laboratory workers who are exposed to rabies virus or who handle specimens considered high risk for rabies, and persons who visit countries where rabies is a significant problem (ie, visits >30 d). (See Table 1, below.)
Table 1. Risk Categories for Active Preexposure Immunization and Rabies Titer Monitoring (Open Table in a new window)
| Category | Target Population | Immunization Regimen | Serologic Testing |
| Continuous | Rabies research laboratory or biologics production workers | Primary course; booster when serum antibody is less than 1:5 dilution based on RFFIT results | Every 6 months |
| Frequent | Rabies diagnostic laboratory workers, spelunkers, veterinarians and staff, animal control and wildlife workers in rabies-enzootic areas, travelers to areas of enzootic rabies for more than 30 days | Primary course; booster every 2 years or when serum antibody is less than 1:5 dilution based on RFFIT results | Every 2 years if not regularly boosted |
| Infrequent | Veterinarians and staff/students, animal control and wildlife workers in areas of low rabies risk | Primary course; no booster | None |
| Rare | US population at large | None | None |
CDC and WHO recommend 2 doses of cell-culture vaccine administered intramuscularly or intradermally on days 0 and 3 for preexposure "booster" prophylaxis.[13]
In the United States, the CDC recommends rabies postexposure prophylaxis only with intramuscular (IM) cell-cultured vaccines; intradermal (ID) formulations are not approved by the US Food and Drug Administration (FDA) for use in the United States.
Outside the United States, in areas where cost and vaccine supply are limiting factors, alternatives to the IM regimens may be more feasible. In addition, rabies vaccination may be the norm in some countries where rabies is endemic, and anamnestic response may permit effective alternative dosing. In 1998, the World Health Organization (WHO) released guidelines for ID use of human diploid cell vaccine (HDCV), purified chick embryo cell vaccine, and purified duck embryo cell vaccine.[26] The WHO published updated postexposure prophylaxis guidelines that included ID regimens often used outside the United States.[27]
Booster immunization is indicated for individuals at continuous or frequent risk of rabies, who should undergo periodic rabies antibody testing and who have serum rabies titer of less than 1:5 dilution based on RFFIT results.
An NAb titer greater than or equal to 0.5 IU/mL (or complete neutralization at a serum dilution of 1:5) is considered an acceptable antibody response for protection against rabies.
Passive immunization consists of the administration of human rabies immunoglobulin (HRIG) pooled from the sera of immunized human donors.
Postexposure Approach to Animal Bites and other Exposures
As previously stated, washing and wound debridement at the time of a bite is essential, along with careful cleaning of the wound for longer than 10 minutes. Generally, leave wounds to heal by secondary intention.[14, 18] Antibiotic prophylaxis should be considered.[18, 28]
Administer HRIG to any person not previously vaccinated against rabies, at a dose of 20 IU/kg (for adults and children). Apply as much of the dose as possible at the injury site and the remainder as a deep IM injection in the gluteal area. HRIG may be administered as long as 7 days after the first dose of vaccine if it is not immediately available when the patient presents for evaluation.[7, 14]
Equine rabies immunoglobulin may be available in other countries. Minimal adverse effects occur if it is in the purified form. If unpurified, however it may cause serum sickness and anaphylaxis.
Two different inactivated rabies vaccines are licensed and produced in the United States, as follows:
- Human diploid cell vaccine (HDCV; Imovax) - Usual dosing for postexposure prophylaxis to be administered as IM injection
- Purified chick embryo cell vaccine (PCEC; RabAvert) - Licensed in the United States in 1997 for IM use only
Doses of all the vaccines for postexposure prophylaxis are 1 mL IM in the deltoid or in the upper outer thigh in infants.
Mild local and systemic adverse reactions to these vaccines and immunoglobulin may occur but are usually treatable with supportive care, antihistamines, and anti-inflammatory medications. Local pain, erythema, headache, nausea, and abdominal pain may occur. If prophylaxis is warranted, do not postpone or discontinue treatment because of mild adverse effects.
Postexposure Prophylaxis or Immunization Before Symptom Onset
Before the onset of rabies symptoms, optimal results require immediate, vigorous wound cleansing; passive immunization with immunoglobulin; and active immunization with rabies vaccine.[13] Children are prone to extensive wounds on the face, upper body, and hands because of their short stature.[29] These wounds may require extensive debridement and inpatient management.
Do not administer immunoglobulin and vaccine with the same syringe or in the same site. Passive immunoglobulin provides protection for 1-2 weeks until the vaccine elicits protective antibody.
If the patient has had no prior rabies vaccination, if he or she is of unknown status, or if more than 5 years have passed since his or her last vaccination, rabies vaccine and immunoglobulin should be administered as follows (these dosages being applicable to products available in the United States):
- Rabies vaccine IM (deltoid) - 1 mL on days on days 0, 3, 7, and 14 (if immunocompromised, add an additional dose: 1 mL IM deltoid on days 0, 3, 7, 14, and 28)
- Rabies immunoglobulin - 20 IU/kg infiltrated as much as feasible around and under the bite wound; if any left over, give IM (gluteus)
If the patient has had prior rabies vaccination, vaccine should be administered as follows (this dosage again being applicable to US vaccine): Rabies vaccine IM (deltoid) 1 mL on days on days 0 and 3.
The pediatric dose of HRIG, calculated by body weight, may be of insufficient volume to infiltrate all of the wounds. The immunoglobulin may be diluted with sterile saline so that more volume can be used without exceeding the total recommended dose.[30]
Empiric treatment for rabies should be guided by local public health recommendations, whenever feasible, taking into account whether viral shedding periods are known for the species, the animal's history and risk for rabies exposure, and local epidemiology. In most settings where rabies is a risk, prophylaxis should be initiated regardless of whether or not the animal is in custody and being observed. Prophylaxis may be discontinued if the animal does not develop rabies within 10 days or is found to be free of rabies upon sacrifice.
Some countries and limited areas in US territories are considered rabies-free, and no prophylaxis is administered. The median duration of rabies illness in dogs, cats, and ferrets is less than 10 days, and viral shedding in saliva occurs within a few days of onset of illness and death.
Because of the exceedingly low prevalence of rabies in domestic animals in the United States, healthy, unvaccinated domestic dogs, cats, and ferrets are often observed for 10 days for signs of illness. If the animal remains healthy, no treatment is administered. Vaccinated animals in the United States have not transmitted rabies; outside the United States, rare instances of transmission occur.
Note that an assessment of whether a bite was provoked is subjective and does not significantly affect the chances that the animal is rabid. Therefore, this is not helpful in determining the need for prophylactic treatment.
Pregnancy is not a contraindication to postexposure prophylaxis against rabies, which is warranted to protect the life of the fetus and mother. No adverse pregnancy outcomes have been documented with postexposure prophylaxis. No mother-to-fetus transmission has been described, and spread of the virus is not hematogenous; thus, neither rabies exposure nor diagnosis in the mother is an indication for pregnancy termination.[31, 32]
Intradermal (ID) regimens have not been approved by the US Food and Drug Administration (FDA) or recommended by the CDC for use in the United States. WHO recommends ID regimens for use outside the United States when IM vaccine is unavailable or its use is not feasible.
In previously vaccinated individuals, studies have shown that single-visit, 4-site ID booster regimens offer satisfactory anamnestic response. A retrospective study at The Queen Saovabha Memorial Institute (QSMI) investigated booster regimens in more than 5000 previously immunized individuals who presented with rabies exposures. The study found that the single-visit, 4-site ID booster regimen using cell-cultured vaccine demonstrated superior anamnestic response, more rapid rise in Nab levels, and more persistently high Nab levels 1 year after prophylaxis than did the standard WHO 2-visit booster regimen.[33] Advantages of the single-visit booster also included reduced time and reduced costs from loss of work or from delayed travel, along with enhanced compliance.
Medical Treatment After Symptom Onset
Inpatient care
Symptomatic rabies cannot be managed in the outpatient setting. Intensive cardiopulmonary supportive care is the only treatment available for patients with symptomatic rabies. Rabies vaccination and administration of HRIG is ineffective at this point. In animal studies, rabies immunoglobulin has been associated with “early death”; it has been suggested that HRIG may also pose a risk of early death in humans and should be avoided.[34]
Regardless of treatment, symptomatic rabies is almost invariably fatal, with autonomic dysfunction leading to cardiac arrhythmia and hypotension. Some role for combination treatments including ribavirin, interferon, ketamine, and immunomodulatory therapies has been proposed and may be considered in future cases under investigational protocols.
The survival of a teenaged girl from Wisconsin received substantial attention in October 2004 as the first reported case of human survival of rabies in the absence of preceding vaccination or postexposure prophylaxis.[35] Notably, she received an investigational regimen of ribavirin, amantadine, and a ketamine-midazolam–induced coma; however, this therapy has not been validated and has not been reproducible. Further, the bat rabies virus isolated in this case may be less neurovirulent than canine or other variants that are responsible for most human cases of rabies.
Reports of failures of what is commonly referred to as the Milwaukee Protocol outnumber successes reported in the lay press, and the CDC has yet to publish information confirming subsequent survivors. In any case, the possibility of successful treatment may be deemed by some to be an improvement over the current standard of care. The University of Wisconsin maintains a rabies registry tracking the use of this treatment and variations of it, and suggests longer survival periods compared with standard therapy in European and US cases. Registry referral information and the Milwaukee Protocol are offered as an open-source document for humanitarian use on the University of Wisconsin Web site (Rabies Registry website).
The rarity of human rabies hinders timely testing of therapies. Immunomodulatory therapies such as rabies immunoglobulin, rabies vaccine, and interferon have not altered outcomes in trials.
Steroids, which are usually indicated in the treatment of local vaccine reactions or cerebral edema, are contraindicated because of increased mortality noted in animal studies and because they reduce the response to the vaccine.
Transfer
For a patient with an illness consistent with rabies, timely diagnostic workup is essential. Transfer to a tertiary care center with high-level intensive care support and clinicians knowledgeable in managing rabies is optimal whenever feasible.
Deterrence and Prevention
In the community
Patient education
The need for adherence to local public health recommendations regarding the control and vaccination of domestic animals and the vaccination of individuals who may be exposed to rabies in their occupation cannot be stressed enough. The case of the Wisconsin survivor, who did not seek medical attention after being bitten, underscores the need for ongoing public education about preventing this almost uniformly fatal infection.
Counsel patients regarding the subjective nature of provocative behavior toward animals. Especially stress avoiding contact with unfamiliar or wild animals. Wild animals seen in areas or at times of day that seem unusual are reason to suspect rabid behavior. Wild animals that are rabid may seem unusually docile or fearless. Hypersalivation, or “foaming at the mouth,” is pathognomonic for rabies but is often absent.
Prompt, vigorous cleansing of any injury or bite from any animal is critical and may reduce the risk of rabies transmission. Provide extensive reassurance after any injury that may be related to rabies transmission. Fear of rabies is primal and is known to induce hysterical reactions that mimic the disease manifestations.
Promote educational efforts at home and at schools teaching children about safety procedures and precautions regarding pets and wild animals. Many communities have programs through camps, schools, and public libraries, as well as information through local health department Web sites.[36] Veterinarians and public health officials are excellent resources for concerns regarding animal rabies prevention.[7, 37]
In addition, the public should be advised to do the following:
- Teach children at an early age not to handle stray animals or wildlife, especially bats found on the ground
- Report any animals that are sick or acting strange to local public health authorities
- Consult public health authorities if a bat is seen in the home at night, even if a bite is not suspected
- Keep pets indoors at night and fenced in or on a leash when outdoors
- Keep pet food and water dishes indoors
- Have professional animal trappers remove bat colonies from homes and barns
- Handle sick or dead animals with heavy gloves and shovels
- Keep trash container lids tight and maintain compost piles away from dwellings
- Wash hands with soap and water after contact with wildlife
- If an animal scratch or bite occurs, especially if due to a bat, fox, raccoon, skunk, or unvaccinated dog or cat, (1) immediately wash the areas vigorously with soap and water and (2) immediately seek the care of a physician. Aside from rabies, bites may become infected, and preventive care is available if sought.
For patient education information, see the Infections Center, as well as Rabies.
Healthcare workers
Universal precautions and respiratory precautions during respiratory therapy are indicated for health care providers. Rabies postexposure prophylaxis of health care workers is indicated only for high-risk exposures as determined with the assistance of local infection control and public health authorities.
Organ transplant recipients
Pretransplantation screening for potential rabies infection or exposure should be performed on organ donors.[7] Recipients of corneal and neurally derived tissues are at highest risk of rapid development of rabies; however, solid organ transplant recipients have also become infected.
Clinical screening of potential organ donors should include a history of animal bites, presence of clinical features of rabies, and a travel history (within a period of months) to areas where rabies is endemic; preexposure rabies immunization of potential organ recipients is being evaluated as an alternative approach to prevent transmission associated with organ transplantation.[11]
Control of rabies in the animal population
Because rabies is a zoonosis, primary prevention requires control of rabies in the animal population. In 1997, approximately 100,000 animal brains were tested for rabies virus antigen using a direct fluorescent assay. Of these specimens, 8509 (8.5%) had positive results.
Mass control and mandatory vaccination of domesticated dogs and cats are effective in controlling rabies in the United States; however, developing nations have found cost to be a barrier to such campaigns.
Live viral vaccines containing modified live rabies or recombinant vaccinia-rabies glycoprotein virus, placed in a bait, are used for disease control in Europe and North America. In the United States, more than 22 million doses of vaccinia-rabies glycoprotein vaccine were distributed between 1990 and 2000. The baits were mainly used to control rabies in raccoons in the eastern United States and in foxes and coyotes in Texas. People will inevitably find vaccine-laden baits. Dogs are frequently attracted to the baits and bring them to their owners. Luckily, adverse events are rare.
Consultations
Consultation with infectious disease specialists, neurologists, and neurosurgeons may be necessary to assist in diagnosis and management of patients with rabies or patients exposed to rabies.
Consultation with public health authorities is appropriate to assist in management of bite wound prophylaxis and animal epidemiology.[38] Also, consult with animal control officers and veterinarians for the management, disposal, and testing of animals that have attacked and injured a human.
Centers for Disease Control and Prevention. Investigation of rabies infections in organ donor and transplant recipients--Alabama, Arkansas, Oklahoma, and Texas, 2004. MMWR Morb Mortal Wkly Rep. Jul 9 2004;53(26):586-9. [Medline].
Srinivasan A, Burton EC, Kuehnert MJ, et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med. Mar 17 2005;352(11):1103-11. [Medline].
Blanton JD, Palmer D, Christian KA, Rupprecht CE. Rabies surveillance in the United States during 2007. J Am Vet Med Assoc. Sep 15 2008;233(6):884-97. [Medline].
Messenger SL, Smith JS, Rupprecht CE. Emerging epidemiology of bat-associated cryptic cases of rabies in humans in the United States. Clin Infect Dis. Sep 15 2002;35(6):738-47. [Medline].
Willoughby RE Jr, Hammarin AL. Prophylaxis against rabies in children exposed to bats. Pediatr Infect Dis J. Dec 2005;24(12):1109-10. [Medline].
McLean RG. Rabies in raccoons in the Southeastern United States. J Infect Dis. Jun 1971;123(6):680-1. [Medline].
National Association of State Public Health Veterinarians. Compendium of animal rabies prevention and control, 2004: National Association of State Public Health Veterinarians, Inc. (NASPHV). MMWR Recomm Rep. Jun 25 2004;53:1-8. [Medline].
Moore DA, Sischo WM, Hunter A, Miles T. Animal bite epidemiology and surveillance for rabies postexposure prophylaxis. J Am Vet Med Assoc. Jul 15 2000;217(2):190-4. [Medline].
Doyle TJ, Bryan RT. Infectious disease morbidity in the US region bordering Mexico, 1990-1998. J Infect Dis. Nov 2000;182(5):1503-10. [Medline].
Rupprecht CE, Blass L, Smith K, et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med. Aug 23 2001;345(8):582-6. [Medline].
Jackson AC. Screening of organ and tissue donors for rabies. Lancet. Dec 11-17 2004;364(9451):2094-5. [Medline].
WHO. WHO expert consultation on rabies. First Report. WHO technical report series. 2004;931:1-121.
WHO. WHO Guide for Rabies Pre- and Post-exposure Prophylaxis in Humans. World Health Organization. Available at http://www.who.int/rabies/PEP_prophylaxis_guidelines_June10.pdf. Accessed October 18, 2010.
Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. May 23 2008;57:1-28. [Medline].
Willoughby RE Jr, Tieves KS, Hoffman GM, et al. Survival after treatment of rabies with induction of coma. N Engl J Med. Jun 16 2005;352(24):2508-14. [Medline]. [Full Text].
McDermid RC, Saxinger L, Lee B, et al. Human rabies encephalitis following bat exposure: failure of therapeutic coma. CMAJ. Feb 26 2008;178(5):557-61. [Medline]. [Full Text].
Hu WT, Willoughby RE Jr, Dhonau H, Mack KJ. Long-term follow-up after treatment of rabies by induction of coma. N Engl J Med. Aug 30 2007;357(9):945-6. [Medline].
Goldstein EJ. Current concepts on animal bites: bacteriology and therapy. Curr Clin Top Infect Dis. 1999;19:99-111. [Medline].
Baer GM. The Natural History of Rabies. Boston, MA: CRC Press; 1991.
Hantson P, Guérit JM, de Tourtchaninoff M, et al. Rabies encephalitis mimicking the electrophysiological pattern of brain death. A case report. Eur Neurol. 1993;33(3):212-7. [Medline].
Hemachudha T. Human rabies: clinical aspects, pathogenesis, and potential therapy. Curr Top Microbiol Immunol. 1994;187:121-43. [Medline].
Willoughby RE, Roy-Burman A, Martin KW, et al. Generalised cranial artery spasm in human rabies. Dev Biol (Basel). 2008;131:367-75. [Medline].
University of Wisconsin. Care of rabies. Version 3.1. Available at http://www.mcw.edu/FileLibrary/Groups/Pediatrics/InfectiousDiseases/Milwaukee_rabies_protocol_V3_1.pdf. Accessed September 2011.
Wacharapluesadee S, Hemachudha T. Nucleic-acid sequence based amplification in the rapid diagnosis of rabies. Lancet. Sep 15 2001;358(9285):892-3. [Medline].
Wacharapluesadee S, Hemachudha T. Urine samples for rabies RNA detection in the diagnosis of rabies in humans. Clin Infect Dis. Mar 15 2002;34(6):874-5. [Medline].
WHO. Guide for post-exposure prophylaxis. World Health Organization. Available at http://www.who.int/rabies/human/postexp/en/. Accessed October 18, 2010.
World Health Organization. Rabnet Database. Department of Communicable Diseases Surveillance and Response. Animal and Food related Public Health Risks. Geneva, Switzerland: World Health Organization; 2001:[Full Text].
Rupprecht CE, Gibbons RV. Clinical practice. Prophylaxis against rabies. N Engl J Med. Dec 16 2004;351(25):2626-35. [Medline].
Fisher DJ. Resurgence of rabies. A historical perspective on rabies in children. Arch Pediatr Adolesc Med. Mar 1995;149(3):306-12. [Medline].
Committee on Infectious Diseases, American Academy of Pediatrics. 2006 Red Book - Report of the Committee on Infectious Diseases. 27. Elk Grove, IL: American Academy of Pediatrics; 2006:552-9.
Arya SC, Agarwal N. Assessing the safety of post-exposure rabies immunization in pregnancy. Hum Vaccin. Sep-Oct 2007;3(5):155; author reply 155. [Medline].
Abazeed ME, Cinti S. Rabies prophylaxis for pregnant women. Emerg Infect Dis. Dec 2007;13(12):1966-7. [Medline]. [Full Text].
Complete List of Vaccines Licensed for Immunization and Distribution in the U.S. Food and Drug Administration. Available at http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm.
Willoughby RE Jr. "Early death" and the contraindication of vaccine during treatment of rabies. Vaccine. Nov 27 2009;27(51):7173-7. [Medline].
Centers for Disease Control and Prevention. Recovery of a patient from clinical rabies--Wisconsin, 2004. MMWR Morb Mortal Wkly Rep. Dec 24 2004;53(50):1171-3. [Medline]. [Full Text].
Dandoy S, Scanlon F. Teaching kids about rabies. Am J Public Health. Mar 1999;89(3):413-4. [Medline].
Murray KO, Arguin PM. Decision-based evaluation of recommendations for preexposure rabies vaccination. J Am Vet Med Assoc. Jan 15 2000;216(2):188-91. [Medline].
Moran GJ, Talan DA, Mower W, et al. Appropriateness of rabies postexposure prophylaxis treatment for animal exposures. Emergency ID Net Study Group. JAMA. Aug 23-30 2000;284(8):1001-7. [Medline].
Prosniak M, Faber M, Hanlon CA, et al. Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis. Jul 1 2003;188(1):53-6. [Medline].
Wilson JM, Hettiarachchi J, Wijesuriya LM. Presenting features and diagnosis of rabies. Lancet. Dec 6 1975;2(7945):1139-40. [Medline].
A Human Monoclonal Antibody to Rabies Virus Provides Protective Neutralizing Activity: Results of a Phase 1 Study, 50th Annual Meeting, Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Boston, MA, 2010.
World Health Organization. Rabies. 2006;Fact Sheet #99:[Full Text].
| Category | Target Population | Immunization Regimen | Serologic Testing |
| Continuous | Rabies research laboratory or biologics production workers | Primary course; booster when serum antibody is less than 1:5 dilution based on RFFIT results | Every 6 months |
| Frequent | Rabies diagnostic laboratory workers, spelunkers, veterinarians and staff, animal control and wildlife workers in rabies-enzootic areas, travelers to areas of enzootic rabies for more than 30 days | Primary course; booster every 2 years or when serum antibody is less than 1:5 dilution based on RFFIT results | Every 2 years if not regularly boosted |
| Infrequent | Veterinarians and staff/students, animal control and wildlife workers in areas of low rabies risk | Primary course; no booster | None |
| Rare | US population at large | None | None |

